Table 1

 Characteristics of patients at baseline

Placebo (n = 34)Ciclosporin (n = 38)
Women, No (%)19 (56)27 (71)
Age (years), mean (SD)47.1 (10.8)46.8 (11.5)
Race (%):
    Caucasian31 (91)35 (92)
    Asian2 (6)3 (8)
    Other1 (3)0 (0)
Disease duration (months), mean (SD)42.4 (41.9)40.8 (33.0)
Dactylitis, No (%)7 (21)7 (18)
Nail dystrophy, No (%)22 (65)22 (58)
Enthesitis, No (%)6 (18)9 (24)
Uveitis, No (%)1 (3)0 (0)
HLA-B27, No (%)9 (26)6 (16)
DR4, No (%)8 (24)11 (29)
Concomitant treatment at baseline:
    NSAIDs, No (%)26 (76)30 (79)
    Prednisolone (⩽10 mg/day), No (%)0 (0)2 (5)
Tender joint index, mean (SD)44.3 (38.2)35.4 (34.8)
Tender joint count, mean (SD)28.3 (19.2)22.6 (15.9)
Swollen joint count, mean (SD)11.7 (8.6)11.7 (9.7)
CRP (mg/l), mean (SD)15.4 (13.3)17.4 (14.5)
PASI score, mean (SD)2.2 (2.7)2 (2.3)
Larsen score, mean (SD)36 (28.7)33 (27)